Introduction {#s1}
============

Obesity and mood disorders represent dominant sources of morbidity and disability. Anxiety disorders are the most common psychiatric condition in developed countries, and their prevalence is significantly increased by the incidence of obesity ([@CIT0011]). Due to their persistent nature, anxiety disorders can be particularly debilitating by impairing not only well-being and quality of life but also intensifying the threat of obesity-related complications. Substantial research efforts have focused on reducing the burden of obesity and associated illnesses, but results have been unsatisfying.

The search for treatments has prompted the study of free fatty acids and their signalling actions at G-protein-coupled receptors (GPCRs). Indeed, fatty acids are not only essential nutritional components, but they also play an important role as signalling molecules that regulate metabolism and inflammation. Specific fatty acid receptors considered orphan GPCRs have been the subject of much recent investigation for their therapeutic potential ([@CIT0005]; [@CIT0043]). Among these are GPR120 (FFAR4) and GPR40 (FFAR1) that are stimulated by long-chain fatty acids, including omega-3 (ω-3) polyunsaturated fatty acids (PUFA) ([@CIT0018]; [@CIT0015]). GPR120 loss-of-function in mice prevents the antiinflammatory and insulin sensitizing actions of ω-3 PUFA ([@CIT0024]), decreases energy expenditure, and increases high-fat diet (HFD)-induced weight gain ([@CIT0016]), whereas variants in the human gene encoding GPR120 increase the risk of obesity ([@CIT0016]) and fasting plasma glucose levels ([@CIT0001]). Further, GPR120 agonism improves insulin resistance and inflammation in high-fat-fed obese mice, suggesting GPR120 as a promising antidiabetes and -obesity target ([@CIT0041]). GPR120 may affect appetite and food intake by regulating the secretion of gut hormones, such as GLP-1 ([@CIT0039]; [@CIT0025]), glucagon ([@CIT0037]), cholecystokinin ([@CIT0039]), and ghrelin ([@CIT0020]; [@CIT0007]; [@CIT0012]). Alternatively, GPR120 could affect feeding and energy balance via direct central actions, although the role of GPR120 in the central nervous system is poorly understood.

Beyond their impact on energy balance, dietary ω-3 PUFA are also well implicated in the regulation of emotional states and pathophysiology of mood disorders. Decreasing brain content of ω-3 PUFA via dietary deficiency enhances anxiety- and depressive-like behaviors ([@CIT0031]; [@CIT0021]; [@CIT0036]), whereas ω-3 dietary supplementation can have anxiolytic actions in rodent and primates ([@CIT0008]; [@CIT0010]; [@CIT0019]). Moreover, saturated high-fat feeding, which can diminish brain ω-3 PUFA concentrations ([@CIT0026]), promotes anxiety-like behavior and greater stress sensitivity in mice ([@CIT0033]; [@CIT0032]; [@CIT0044]). The objective of the present study was to determine the role of brain GPR120 in the control of appetite, energy balance, and anxiety-like behavior. Here, we demonstrate that pharmacological activation of central GPR120 can profoundly inhibit food intake and the rewarding effects of high-fat/-sugar food on the short term and sustained actions to reduce anxiety-like behavior in high-fat-fed mice.

Materials and Methods {#s2}
=====================

Animals {#s3}
-------

All procedures were approved by the Institutional Animal Care Committee of the CRCHUM that adheres to the standards of the Canadian Council on Animal Care. Male C57Bl/6 mice (Charles River, St Constant, Canada) received at 7 to 8 weeks of age were maintained in an environmentally controlled room (22--24ºC) with ad libitum access to standard chow and water. Mice were acclimated to a reverse light/dark cycle for at least 7 days before initiation of experiments and were individually housed following intracerebroventricular (ICV) cannula implantation. All behavioral testing was carried out in the dark phase.

ICV Cannula and Osmotic Mini-Pump Implantation {#s4}
----------------------------------------------

Mice were anaesthetized with isoflurane and placed in an ultraprecise mouse stereotaxic apparatus (Kopf Instruments). For acute agonist treatment experiments, a single ICV cannula was implanted. With Bregma and Lambda in the same horizontal plane, a cannula (guide cannula: C315GS-5-SP, 5mm, 26 gauge, Plastics One) was lowered into the lateral ventricle (+0.5mm caudal and +1mm lateral to bregma; -2mm ventral), fixed to the skull with cyanoacrylate glue and Cerabond adhesive (Plastics One) and closed with an adapted dust cap (Dummy cannula: C315DCS-5-SPC, 4mm, 33 gauge, Plastics One). Five days following the surgery, the placement of cannulas was verified by the drinking response to an injection of Angiotensin II (10ng/µL; Sigma). For chronic agonist administration, ICV cannulae with an L-shaped adaptor (Alzet, 28 gauge, 3--5mm from skull surface) were attached to a primed 21-day osmotic mini-pump with a flow rate of 0.25 µL/h (Alzet osmotic pump catalog \#1002) via polyethylene tubing that was prefilled with vehicle. Fluid movement through the assembly was verified at the cannula tip prior to stereotaxic implantation as described above. The mini-pump was inserted underneath the skin and pushed into place between the scapulae.

Drugs {#s5}
-----

The GPR120 agonist (GPR120 III) was purchased from Calbiochem (San Diego, CA). GPR120 III is a potent agonist of GPR120 (EC50 =17nM) that exhibits minor affinity for GPR40 (EC50 = 64.6 µM) and no activity toward short chain fatty acid receptors ([@CIT0035]). Despite the much reduced potency toward GPR40 of the GPR120 agonist, we also tested the central effects of the specific GPR40 agonist, TAK-875 (Selleckchem) ([@CIT0023]) on food intake. All drugs were dissolved in saline + 1% dimethylsulfoxide (DMSO)..

Food Intake {#s6}
-----------

The effects of acute ICV injections of GPR120 and GPR40 agonists on food intake were assessed. The 0.1- and 1-µM doses of GPR120 agonist selected correspond to those reported to inhibit formalin-induced pain upon ICV injection ([@CIT0022]). Via an internal injector cannula attached to a 1-µl Hamilton microsyringe, mice (n=11) received 1 µL of vehicle (saline + 1% DMSO) on day 1 followed by 0.1 μM of the GPR120 agonist on day 3 and then 1 µM of GPR120 agonist on day 5 (1-day recovery period between each injection). Three days later, the same mice were again injected with vehicle and then the GPR40 agonist (1 μM) 2 days later. Single-housed mice were initially habituated to bedding-free cages with absorbent padding (for accurate food intake measurements) prior to testing. ICV injections were performed in fed mice at the beginning of the dark cycle. Following injections, chow intake was measured at 1, 2, 4, 6, 12, and 24 hours postinjection.

Locomotor Activity {#s7}
------------------

Mice were habituated to metabolic cages (Comprehensive Lab Animal Monitoring System CLAMS, Columbus, OH) for 2 days prior to testing. Locomotor activity (X-Y-Z beambreaks) was measured for 12 hours following ICV injection of GPR120 agonist or vehicle.

Real-Time Quantitative PCR {#s8}
--------------------------

Brain punches of all specified regions were obtained from 250-μM frozen coronal sections. Tissues were further processed for mRNA extraction (TRIzol) and cDNA synthesis to perform quantitative PCR as described ([@CIT0009]) using the following primer sequences: *β-Actin*, F: TTCTTGGGTATGGAATCCTGTGGCA; R: ACCAGACAGCACTGTGTTGGCATA and *GPR120*, F: AGAGGCT TACGCTGAGCTTG; R: TGGATCAAGATGAGGATG. Relative gene expression was calculated using the ΔΔCT method using *B-actin* as the housekeeping gene.

Food-Motivated Behavior {#s9}
-----------------------

Mice were trained to press an ultra-light retractable lever for food rewards (14mg high-fat, high-sucrose pellets, Bio-Serv) in mouse operant cages (Med Associates, Inc.) on a progressive ratio (PR) schedule of reinforcement as described previously ([@CIT0034]). Briefly, mice were mildly food restricted to acquire the lever-pressing task on a fixed-ratio-1 followed by a fixed-ratio-5 and PR schedules of reinforcement. Mice were returned to ad libitum feeding conditions during PR training. Once stable responding on the PR schedule was achieved, mice were first tested in basal conditions without injection (day 1) and then following injection of vehicle (day 2) and the GPR120 agonist (1 µg; day 3). ICV injections were carried out 1 hour before testing. The number of active lever presses, rewards earned, and the breakpoint ratio (last ratio successfully completed) were calculated by MedPC software (Med Associates, Inc).

Anxiety: Elevated Plus Maze {#s10}
---------------------------

Mice were placed in the middle of the elevated-plus maze (EPM; Med Associates, Inc., St Albans, VT) facing the open arm opposing the experimenter 1 hour following ICV injections. Movement in the maze was recorded and tracked for 5 minutes by an overhead video camera connected to a PC with Ethovision XT software. Mice with mini-pumps followed the same procedure but without injection prior to the test.

Anxiety: Open Field Test {#s11}
------------------------

The open field test (OFT) was used as an additional measure of anxiety-like behavior as previously described ([@CIT0033]). Briefly, each mouse was placed in the middle of the arena 1 hour after injection and allowed to explore the field. Time spent in the center of the arena, center entries, plus the time and frequency of stretched attend postures (body elongation, an important component of defensive behavior in rodents) during the first 5 minutes of this test were used as measures of exploration that serve as indices of anxiety. Behavior was recorded and tracked by an overhead video camera connected to a PC with Ethovision XT software. Mice with mini-pumps followed the same procedure but without injection prior to the test.

Mini-Pump ICV Infusions {#s12}
-----------------------

Mini-pumps delivered either vehicle or GPR120 agonist (1 µM/d; \~42nM/h) at a flow rate of 0.25 µL/h into the lateral ventricle. Food intake and body weight measures began 3 days following cannula and mini-pump implantation. Mice initially fed a chow diet were separated into 3 weight-matched groups (n=5--8/group): (1) vehicle infusion on an ingredient-matched, low-fat diet (LFD; 4.07 kcal/gm: 10.5% kcal fat, 16.4% kcal protein, 73.1% kcal carbohydrates, D12328, Research Diets, Inc., New Brunswick, NJ); (2) vehicle infusion on a HFD (5.56 kcal/gm: 58% kcal fat, 16.4% kcal protein, 25.5% kcal carbohydrates, D12331, Research Diets, Inc.); and (3) GPR120 agonist infusion on a HFD. Mice received their respective diet for 3 weeks.

Statistical Analyses {#s13}
--------------------

Statistics were calculated using GraphPad Prism 6 (San Diego, CA). The effects of agonists on short-term food intake were analyzed by 1 -way ANOVAs with posthoc Dunnett tests. Anxiety-like behavior following acute injection was assessed by 2-tailed, paired *t*-tests. A 2-way ANOVA with the Bonferroni posttests was used for food intake, body weight, and energy expenditure data, whereas a 1-way ANOVA plus Bonferonni posttests was used for comparisons of anxiety-like behavior following prolonged pump treatment. Data are presented as mean ± SEM and *P ≤* .05 was set as the criteria for statistical significance.

Results {#s14}
=======

Central GPR120 Agonism Inhibits Food Intake {#s15}
-------------------------------------------

Food intake at 1, 2, and 4 hours postinjection was significantly decreased in chow-fed mice receiving an ICV bolus of the GPR120 agonist at each of the 2 doses compared with controls ([Figure 1A](#F1){ref-type="fig"}). GPR120 agonist treatment elicited up to an 80% and 72% reduction in food intake at the first and second hour postinjection, respectively ([Figure 1A](#F1){ref-type="fig"}) (*P*\<.001). In contrast, the GPR40 agonist did not affect food intake at any time point ([Figure 1B](#F1){ref-type="fig"}). To determine if central GPR120 stimulation affects ambulatory activity, we next examined basal locomotion. Agonist-injected mice exhibited a trend (*P*=.1) for increased activity only during the first hour postinjection ([Figure 1C](#F1){ref-type="fig"}).

![Central injection of a GPR120 agonist acutely inhibits food intake. (A) Cumulative food intake following acute central agonist injection. GPR120 agonist treatment elicited up to an 80% and 72% reduction in food intake at the first and second hour postinjection, respectively (n=11). (B) A selective GPR40 agonist (1 μM) did not influence food intake (n=9). (C) A single ICV injection of the GPR120 agonist had no overall effect on locomotor activity; however, it produced a trend (*P*=.1) for increased ambulatory activity during the first hour postinjection (n=5/group). Mean ± SEM; \**P*\<.05, \*\*\* *P*\<.001.](ijnppy_pyw014_f0001){#F1}

*GPR120* Is Expressed in Reward-Related Nuclei and Influences Food-Motivated Behavior {#s16}
-------------------------------------------------------------------------------------

The consumption of rewarding, energy-dense food is a major factor contributing to overeating and the development obesity and associated anxiety-like behavior ([@CIT0033]). First, we sought to determine if *GPR120* is expressed in brain areas important for the control of food reward and mood in addition to its reported expression in the hypothalamus ([@CIT0004]). Consistent with previous reports, we found relatively high expression of *GPR120* mRNA in the arcuate nucleus (ARC) of the hypothalamus. *GPR120* was also comparatively elevated in the nucleus accumbens (NAc), a brain region well implicated in the control of motivation and mood, with lesser and minimal expression in the hippocampus and ventral tegmental area, respectively ([Figure 2A](#F2){ref-type="fig"}). We next ascertained if central GPR120 agonism decreases the motivational effects of palatable food using an operant conditioning task in which mice press a lever to receive high-fat/-sugar pellets on a PR schedule of reinforcement. Agonist treatment did not affect the proportion of active and inactive lever presses ([Figure 2B](#F2){ref-type="fig"}), suggesting there were no changes in operant learning; however, it substantially reduced the number of rewards earned ([Figure 2C](#F2){ref-type="fig"}; *P*\<.05) and breakpoint response thresholds ([Figure 2D](#F2){ref-type="fig"}; *P*\<.05) relative to vehicle-injected controls.

![*GPR120* is expressed in reward-relevant nuclei, and central agonism inhibits the rewarding effect of palatable food. (A) *GPR120* mRNA expression in the arcuate nucleus (ARC), ventral tegmental area, hippocampus, and the nucleus accumbens (NAc) (n=4/group). (B) Central injection of the GPR120 agonist (1 μM) did not impair operant learning as reflected by the proportion of correct and incorrect lever responses (n=7). (C) GPR120 agonism reduced the number of high-fat/-sucrose pellet rewards on progressive ratio (PR) schedule of reinforcement as compared to vehicle treatment. Vehicle treatment did not alter rewards earned relative to baseline testing (n=7). (D) Breakpoint response thresholds (maximum response ratio at which point mice will work to obtain the reward) in the PR task were suppressed by GPR120 agonist injection (n=7). Mean ± SEM. \**P*\<.05.](ijnppy_pyw014_f0002){#F2}

Central GPR120 Agonism Dampens Conflict Behavior {#s17}
------------------------------------------------

In view of the anxiolytic actions associated with dietary ω-3 PUFA, we sought to determine if central GPR120 stimulation modulates anxiety-like behavior using 2 standard tests of anxiety: the EPM and OFT. Acute agonist injection produced a trend (*P*=.1) for increased time spent in the open arms of the EPM ([Figure 3A](#F3){ref-type="fig"}) without altering open arm entries ([Figure 3B](#F3){ref-type="fig"}). The amount of time spent in the center of the OFT and the number of center entries were not different between groups ([Figure 3C](#F3){ref-type="fig"}-D); however, the duration ([Figure 3E](#F3){ref-type="fig"}, *P*\<.01) and frequency ([Figure 3F](#F3){ref-type="fig"}, *P*\<.01) of stretch attend postures, classified as an approach-avoidance element of conflict behavior ([@CIT0013]), in the OFT were substantially reduced in agonist-injected mice relative to controls. Horizontal locomotor activity on the OFT was not different between groups ([Figure 3G](#F3){ref-type="fig"}).

![GPR120 agonist injection dampens signs of anxiety-like behavior. (A) GPR120 agonist (1 µM) injection produces a trend (*P*=.1) for increased time spent in the open arms of the elevated-plus maze (EPM) (n=7). (B) GPR120 agonist did not alter open arm entries in the EPM (n=7). (C) The proportion of time spent the center of the open field was unchanged (n=7). (D) The number of center entries in the open field was not different. (E) The duration of stretch attend postures (elongation) was suppressed by the agonist (n=7). (F) The frequency of stretch attend postures was inhibited by the agonist (n=7). (G) Horizontal locomotor activity in the open field test (OFT) was not different between groups. Mean ± SEM. \*\**P*\<.01.](ijnppy_pyw014_f0003){#F3}

Prolonged Central GPR120 Agonism Fails to Affect Energy Balance on a HFD {#s18}
------------------------------------------------------------------------

Administration of a GPR120 oral agonist was recently reported to have greater metabolic actions in the context of a HFD ([@CIT0041]); thus, we next assessed the effects of prolonged central agonist infusion on energy balance parameters in high-fat-fed mice. Free-feeding intake, body weight, respiratory exchange, and locomotor activity were measured in mice with osmotic mini-pumps connected to ICV cannula that delivered either the GPR120 agonist or vehicle ([Figure 4A](#F4){ref-type="fig"}). As shown in [Figure 4B](#F4){ref-type="fig"}, exposure to the HFD increased caloric intake relative to LFD-fed controls as expected (day 11--15: *P*\<.05); however, food intake on the HFD was similar between agonist and vehicle-treated mice. Likewise, body weight increased on HFD but weight gain was similar between groups ([Figure 4C](#F4){ref-type="fig"}). Consistent with greater utilization of lipids, the respiratory exchange ratio measured 2 weeks following the pump infusions decreased with HFD (*P*\<.01) yet was comparable between agonist- and vehicle-treated HFD mice ([Figure 4D](#F4){ref-type="fig"}). Finally, locomotor activity that was measured in parallel with respiratory exchange ratio was similar across groups ([Figure 4E](#F4){ref-type="fig"}).

![Chronic GPR120 administration does not affect food intake, body weight, or energy expenditure. (A) Graphic timeline illustrating experimental protocol following implant of 21-day osmotic mini-pump. (B) Two-week central GPR120 agonist infusions (1 μM/d) did not affect high-fat diet (HFD) consumption. HFD increased caloric intake relative to low-fat diet (LFD) controls (n=5--8/group). (C) GPR120 agonist infusions did not modulate body weight in high-fat-fed mice. (D) The respiratory exchange ratio was not altered by agonist infusions; however, respiratory exchange ratio was increased by HFD relative to LFD consistent with greater lipid utilization (n=5--8/group). (E) Locomotor activity was unchanged by agonist infusions and HFD (n=5--8/group). Mean ± SEM. CLAMS, comprehensive lab animal monitoring system; EPM, elevated-plus maze; OFT, open field test.](ijnppy_pyw014_f0004){#F4}

Prolonged Central GPR120 Activation Inhibits Anxiety-Like Behavior on a HFD {#s19}
---------------------------------------------------------------------------

Anxiety-like behavior was assessed in the EPM and OFT following mini-pump infusions. As shown in [Figure 5A](#F5){ref-type="fig"}, GPR120 agonist infusion reduced the proportion of time spent in the open arms of the EPM without changing open arm entries ([Figure 5B](#F5){ref-type="fig"}) (*P*\<.05). Similarly, the amount of time spent in the center of the OFT was significantly decreased in agonist-treated mice ([Figure 5C](#F5){ref-type="fig"}, *P*\<.05) without any changes in center entries ([Figure 5D](#F5){ref-type="fig"}). There were no differences in the stretch attend posture measure of conflict behavior between groups ([Figure 5E](#F5){ref-type="fig"}-F). Finally, to determine if high-fat feeding and prolonged GPR120 agonism alters *GPR120* expression, we evaluated mRNA expression in the NAc and mediobasal hypothalamus (region including ARC, ventromedial hypothalamus, and dorsomedial hypothalamus), two brain regions in which we found relatively higher *GPR120* expression. No differences were found between group despite a tendency for HFD to decrease *GPR120* expression and for the agonist to increase it.

![Prolonged central GPR120 agonist infusion reduces anxiety-like behavior. (A) Mice receiving the GPR120 agonist spent more time in the open arms of the elevated-plus maze (EPM) relative to high-fat diet (HFD) controls (n=5--8/group). (B) Open arm entries in the EPM were not significantly different between groups (n=5--8/group). (C) Proportion of time spent in the center of the open field was increased in HFD mice receiving the GPR120 agonist relative to HFD mice receiving vehicle (n=5--8/group). (D) The number of center entries was unchanged across groups (n=5--8/group). (E) Duration of stretch attends posture was not different between groups (n=5--8/group). (F) Frequency of stretch attends postures was unchanged between groups (n=5--8/group). (G) *GPR120* mRNA expression following 21-day agonist or vehicle infusions. MBH, mediobasal hypothalamus; NAc, nucleus accumbens. Mean ± SEM. \**P*\<.05.](ijnppy_pyw014_f0005){#F5}

Discussion {#s20}
==========

Several lines of evidence implicate GPR120 in the regulation of energy homeostasis including the control of glycemia and gut hormone secretion ([@CIT0040]). Here, we demonstrate the consequences of acute and chronic central GPR120 stimulation on appetite, energy expenditure, and anxiety. In addition to eliciting a sizeable reduction in food intake, acute stimulation of GPR120 potently decreased the motivational and rewarding effects of palatable food and blunted approach avoidance conflict behavior. Chronic central infusions of the agonist in the context of high-fat feeding produced more robust anxiolytic effects yet failed to affect free-feeding intake, energy expenditure, and body weight on a HFD. Collectively, these results demonstrate the anxiolytic actions of central pharmacological GPR120 stimulation and reveal its central appetite-suppressing effects, which may be limited to transient receptor activation.

A limitation of our study is the use of a GPR120 agonist that weakly binds to GPR40. However, as central administration of a GPR40 specific agonist did not affect food intake, the strong anorectic effects observed are likely attributable to GPR120 activation. The anorectic effect of central GPR120 stimulation is consistent with reports that ω-3 PUFA, including docosahexaenoic acid and eicosapentaenoic acid, but not saturated fatty acids, inhibit food intake upon acute central administration ([@CIT0030]; [@CIT0004]). This raises the possibility that ω-3 PUFA inhibit feeding by targeting GPR120 in brain regions important for controlling food intake. Correspondingly, we found *GPR120* mRNA to be expressed at relatively high levels in the ARC nucleus of the hypothalamus, a finding that coincides with observations of GPR120 protein expression in ARC neuropeptide-Y neurons ([@CIT0004]). Moreover, acute ICV injections of PUFA increased GPR120 association with β-arrestin-2, a GPCR regulatory protein that directly couples to GPR120 ([@CIT0038]) in the hypothalamus ([@CIT0004]). We also noted relatively elevated levels of *GPR120* in the NAc, a key brain site controlling mood and goal-directed behavior for food. In line with these data, we extended the appetite-suppressing effects of central GPR120 agonist treatment to decreased motivation to obtain palatable high-fat and -sugar food using an operant task. Thus, apart from the implication of GPR120 in the stimulation of gut hormones that can modulate feeding, our data suggest that direct activation of central GPR120 can reduce appetite, in part, by suppressing the rewarding effects of palatable food. Future studies are required to determine if decreased food-motivated behavior by GPR120 occurs via signaling actions in the NAc.

Contrary to the impact of acute GPR120 activation on food intake, we did not detect changes in feeding in high-fat-fed mice receiving prolonged agonist treatment. High-fat feeding increased caloric intake, body weight, and respiratory exchange (consistent with increased lipid utilization) as expected, but continuous central GPR120 infusion did not affect these parameters or locomotor activity. In contrast, chronic GPR120 agonist infusion reduced anxiety-like behavior in two standardized tests, having a greater anxiolytic impact compared with the discrete effect on approach-avoidance behavior observed following acute agonist treatment. Thus, the anxiolytic actions of central GPR120 agonism require sustained or cumulative stimulation of GPR120. Consistent with these anxiolytic actions, we found that *GPR120* is expressed in nuclei such as the NAc that are well implicated in the control of emotional processes and mood ([@CIT0029]). No significant differences were observed in *GPR120* gene expression with high-fat feeding and agonist treatment due to highly variable expression levels in the LFD group. Nonetheless, the tendency for *GPR120* in the NAc and mediobasal hypothalamus to decrease in HFD mice and approach LFD levels after agonist infusions argues for further analyses of expression patterns under different dietary conditions.

A possible explanation for the lack of maintained anorectic effects with prolonged GPR120 stimulation could be the presence of counter-regulatory mechanisms that offset catabolic conditions to maintain energy homeostasis. An alternative possibility involves GPR120 desensitization. Desensitization of GPCRs and decreased responsiveness to agonists has been noted in several systems and involves reduced binding of β-arrestins ([@CIT0027]). As noted above, the anorectic effects of acute ICV PUFA injections have been linked to GPR120 activation and association with β-arrestin-2 ([@CIT0004]); however, long-term treatment and receptor binding may diminish β-arrestin signaling and lead to GPR120 resistance. Indeed, HFD consumption is unchanged in GPR120 knockout mice ([@CIT0016]). Moreover, while body weight on a HFD was found to be elevated in one study of GPR120 knockout mice (associated with decreased energy expenditure; [@CIT0016]), others report no changes in body weight following *GPR120* gene deletion ([@CIT0024]) or with prolonged treatment of a GPR120 oral agonist ([@CIT0041]).

The anxiolytic actions of prolonged central GPR120 stimulation suggest that potential GPR120 desensitization does not affect this behavioral function. These findings could suggest that distinct signaling mechanisms may mediate GPR120 action on feeding vs anxiety. The antiinflammatory effects and benefits of the GPR120 activation by ω-3 PUFA involve several mechanisms, including inhibition of the NFkB pathway by β-arrestin ([@CIT0024]); the activation of phospholipase A2, which releases ω-3 PUFA (docosahexaenoic acid and EPA) esterified in membrane phospholipids ([@CIT0017]); and induction of enzyme stearoyl-CoA desaturase-1 generating monounsaturated fatty acids ([@CIT0016]). Central inflammatory processes are well implicated in the etiology of mood disorders, and the beneficial influence of ω-3 dietary supplementation on emotional states has been linked to antiinflammatory actions in the CNS ([@CIT0014]; [@CIT0002]; [@CIT0028]). Indeed, GPR120 was recently identified as having antiinflammatory properties in neural cell lines ([@CIT0042]). GPR120 is highly expressed in peripheral macrophages and may therefore also localize to brain macrophages (notably microglia) to modulate inflammatory processes. Although purely speculative, it is possible that the anxiolytic actions of chronic GPR120 activation implicate distinct antiinflammatory signaling pathways in brain microglia that are not subject to GPR120 desensitization.

Targeting fatty acid receptors is proclaimed as a promising avenue to pharmaceutically treat metabolic diseases. The present study demonstrates that sustained GPR120 agonism in the brain can decrease anxiety-like behavior and thus suggests GPR120 as potential pathway through which ω-3 PUFA have central anxiolytic actions. An emerging element in the treatment of obesity is its strong link with mood disorders and the advantages of an integrated therapeutic approach. The concept of a multi-target strategy is developing and consists of simultaneously producing beneficial effects on energy balance and mood. A GPR120 agonist that can cross the blood brain barrier offers the advantage of this poly-target approach. Our data favor testing compounds that cross the blood brain barrier to target GPR120 and/or downstream effectors for the treatment of anxiety.
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